EODData

MEMBERSHIP REGISTER LOG IN

LSE, 0MTD: Swedish Orphan Biovitrum AB (Publ)

10 Nov 2025
LAST:

331.4

CHANGE:
 5.40		OPEN:
332.7		HIGH:
332.7		ASK:
136.0		VOLUME:
7.9K
CHG(%):
1.66		PREV:
326.0		LOW:
329.2		BID:
131.5		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
10 Nov 25332.7332.7329.2331.47.9K
07 Nov 25327.8330.4321.2326.040.1K
06 Nov 25329.8330.0326.8328.4195.7K
05 Nov 25327.8330.4326.8328.655.9K
04 Nov 25326.4333.8325.4333.889.0K
03 Nov 25325.9329.7323.6326.1101.2K
31 Oct 25331.6331.6326.4326.41.2K
30 Oct 25327.2330.7325.3330.35.4K
29 Oct 25325.4329.5324.6329.273.2K
28 Oct 25323.7326.2323.2323.935.4K

COMPANY PROFILE

Name:Swedish Orphan Biovitrum AB (Publ)
About:Swedish Orphan Biovitrum AB (publ), a biopharma company, provides medicines in the areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. The company operates through three segments: Haematology, Immunology, and Specialty Care. It offers Alprolix for haemophilia B; ALTUVOCT for the treatment and prophylaxis of bleeding in patients with haemophilia A; Aspaveli/Empaveli for treating adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet for the treatment of immune thrombocytopenia and thrombocytopenia; Elocta/Eloctate for the treatment and prophylaxis of bleeding in patients with haemophilia A; Gamifant for treating hemophagocytic lymphohistiocytosis; Kineret for the treatment of cryopyrin-associated periodic syndrome, rheumatoid arthritis, familial Mediterranean fever, deficiency of interleukin-1 receptor antagonist, and systemic juvenile idiopathic arthritis; Orfadin for hereditary tyrosinemia type 1 and alkaptonuria; Synagis for the prevention of serious lower respiratory tract infection caused by respiratory syncytial virus in infants and young children; VONJO, a kinase inhibitor indicated for the treatment of post-polycythemia vera or post-essential thrombocythemia myelofibrosis; and Zynlonta for treating adult patients with relapsed or refractory diffuse large and high grade B-cell lymphoma. The company also provides other medicines, such as Akynzeo, Aloxi, Jyseleca, Kepivance, Tegsedi, and Waylivra, as well as develops drug substances for ReFacto AF/Xyntha for Pfizer. The company has collaboration agreements with Sanofi, Apellis Pharmaceuticals, Inc., ADC Therapeutics SA, and Cartesian Therapeutics, Inc. Swedish Orphan Biovitrum AB (publ) was incorporated in 1939 and is headquartered in Stockholm, Sweden.
Address:Norra Stationsgatan 93A, Stockholm, Sweden
Website:https://www.sobi.com
ISIN:SE0000872095
LEI:549300124Y3MQI87PT35

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:33.51 
PEG Ratio:0.19 
Price to Sales:5.87 
Price to Book:3.41 
Profit Margin:0.16 
Operating Margin:0.24 
Return on Assets:0.05 
Return on Equity:0.12 
Revenue:20.10B 
EBITDA:9.751B 

TECHNICAL INDICATORS

MA5:329.640.5%
MA10:328.410.9%
MA20:319.573.7%
MA50:299.0410.8%
MA100:290.1914.2%
MA200:292.9813.1%
STO9:69.23
STO14:88.12 
RSI14:68.10 
WPR14:-11.88 
MTM14:15.70
ROC14:0.05 
ATR:6.17 
Week High:333.800.7%
Week Low:321.203.2%
Month High:333.800.7%
Month Low:293.8013.1%
Year High:345.204.2%
Year Low:242.6036.6%

RECENT SPLITS

Date Ratio
29 Aug 2023290-277
03 May 2011837-749
07 Dec 2009717-359